May 27, 2009 — The US Food and Drug Administration (FDA) has approved risperidone long-acting injection for use alone or with lithium or valproate in the treatment of bipolar I disorder; and ...
The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial ...
ATLANTA, Oct. 18, 2013 -- regulated information – UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Cimzia® (certolizumab pegol) for the treatment of adults with active ...
UCB (UCB.BR) The European marketing authorisation application for Cimzia® has been filed. Subject to approval, Cimzia® will be the first and only PEGylated, Fc-Free anti-TNF (Tumour Necrosis Factor ...
A self-injection pen prefilled with Brussels-based UCB’s Cimzia (certolizumab pegol) has been made available this week in the U.K. after a positive opinion from the EMA. UCB developed the AutoClicks ...
* EMA has recommended the Cimzia dose dispenser cartridge for use with the re-usable ava electronic injection device in all approved indications Source text: bit.ly/2qcXlVg Further company coverage: ...
LONDON, Feb 6 (Reuters) - Belgian drugmaker UCB is still hoping to launch its Crohn's disease drug Cimzia in the United States in the first half of 2007 and does not think further clinical trials will ...
The FDA has approved Cimzia (certolizumab pegol; UCB) injection for the treatment of adults with non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results